Catalyst Free Cash Flow from 2010 to 2024

CPRX Stock  USD 15.92  0.22  1.36%   
Catalyst Pharmaceuticals Free Cash Flow yearly trend continues to be fairly stable with very little volatility. Free Cash Flow is likely to outpace its year average in 2024. Free Cash Flow is the amount of cash Catalyst Pharmaceuticals generates after accounting for cash outflows to support operations and maintain its capital assets. View All Fundamentals
 
Free Cash Flow  
First Reported
2006-09-30
Previous Quarter
19.6 M
Current Value
31.7 M
Quarterly Volatility
2.3 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many exotic indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Catalyst Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Catalyst Pharmaceuticals Technical models . Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Free Cash Flow Growth Pattern

Below is the plot of the Free Cash Flow of Catalyst Pharmaceuticals over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. Catalyst Pharmaceuticals' Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow10 Years Trend
Pretty Stable
   Free Cash Flow   
       Timeline  

Catalyst Free Cash Flow Regression Statistics

Arithmetic Mean2,596,503
Coefficient Of Variation1,712
Mean Deviation32,613,141
Median(9,885,106)
Standard Deviation44,456,189
Sample Variance1976.4T
Range170.9M
R-Value0.18
Mean Square Error2062.1T
R-Squared0.03
Significance0.53
Slope1,754,859
Total Sum of Squares27668.9T

Catalyst Free Cash Flow History

2024-52.2 M
2023-54.9 M
2022116 M
202159.4 M
202045 M
201934.6 M
2018-25.8 M

Other Fundumenentals of Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Free Cash Flow component correlations

About Catalyst Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Catalyst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Catalyst Pharmaceuticals investors use historical funamental indicators, such as Catalyst Pharmaceuticals's Free Cash Flow, to determine how well the company is positioned to perform in the future. Although Catalyst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Catalyst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Catalyst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Catalyst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Free Cash Flow-54.9 M-52.2 M
Free Cash Flow Yield(0.03)(0.03)
Free Cash Flow Per Share(0.52)(0.49)
EV To Free Cash Flow(30.09)(28.58)
Price To Free Cash Flows Ratio(32.53)(30.90)
Free Cash Flow Operating Cash Flow Ratio(0.38)(0.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock:
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Catalyst Stock analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Money Managers
Screen money managers from public funds and ETFs managed around the world
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.27)
Earnings Share
0.56
Revenue Per Share
3.771
Quarterly Revenue Growth
0.154
Return On Assets
0.0929
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.